IFN-λ therapy for GvHD, mechanism of decitabine in ITP, and TET2 mutations in chronic NK-LGL leukemia

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Can Toia Shut Herbie Down? Penrith's Vulnerable State & Moses' Lebanon Exit!| NRL Daily 47 min · 24 Sep 2026 · Triple M Rocks Footy NRL

Ask, Tell, Confess: I Can't Believe He CHEATED?! 31 min · 24 Sep 2026 · Dumb Blonde

NPR News: 09-23-2026 10PM EDT 4 min · 24 Sep 2026 · NPR News Now

10PM ET 09/23/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Xi in Washington, US-China Trade Truce Extended, More 8 min · 24 Sep 2026 · Bloomberg News Now

Whateley in a Snapshot | Thursday (24.09.26) 6 min · 24 Sep 2026 · Whateley

Report any issue

Source

Recorded26 Aug 2021

Publisherfeeds.transistor.fm ↗

Handlerec:11742125

Show notes

In this week's episode, we will review a study that proposes IFN-λ therapy as a novel strategy to boost gut protection in GvHD, examine the immunomodulatory effects of decitabine in ITP, and learn about the discovery of TET2 mutations in chronic natural killer large granular lymphocyte leukemia

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in